ABSTRACT
Corinfar-retard as a base of different combinations with triampur, Cordanum, Capoten were studied in 52 patients with stable arterial hypertension (systolic pressure > 180 mm Hg, diastolic pressure > 105 mm Hg). In the above combinations pharmacokinetics of corinfar-retard did not change. Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia. In patients with impaired myocardial contractility, elevated total peripheral vascular resistance, noticeable hypotensive effects was registered in combination with triampur. The absence of hypotensive effect in the above combination required the addition of Capoten which was absolutely indicated in patients with stable increase in plasma renin activity.
Subject(s)
Antihypertensive Agents/therapeutic use , Captopril/therapeutic use , Hydrochlorothiazide/therapeutic use , Nifedipine/therapeutic use , Propanolamines/therapeutic use , Triamterene/therapeutic use , Adult , Aged , Antihypertensive Agents/pharmacokinetics , Delayed-Action Preparations , Drug Combinations , Drug Therapy, Combination , Female , Hemodynamics/drug effects , Humans , Hypertension/blood , Hypertension/drug therapy , Hypertension/physiopathology , Male , Middle Aged , Nifedipine/pharmacokinetics , Time FactorsABSTRACT
The long-acting corinfar formulation, corinfar-retard tablets, 20 mg (AWD, Germany), was studied for pharmacokinetics in single and course use in 40 patients with arterial hypertension, as well as for its effects of cordanum and triampur. Patients' plasma corinfar was measured by high performance liquid chromatography. There were no changes in the pharmacokinetics of the agent when it was used in its course use. Cordanum and triampur was demonstrated to have no effects on the pharmacokinetics of corinfar during their application.